Anne Ørbo

Anne Ørbo

Professor

Phone (+47)
77627220

E-mail
anne.orbo@fagmed.uit.no

Office
A1 762 (UNN)

Qualifications
PhD in 1995 University of Tromsø with thesis: Distribution of cyclic AMP and cyclic GMP across the cell membrane. An in vitro study with special reference to cancer of the uterine cervix, cell density, sex steroid hormones and drugs as transport-mediators

Medical specialities: In Gynaecology and Obstetrics -1987
In Pathology- 1989
In Gynaecologic oncology (speciality not formal in Norway) 1990 – 1997

Professor of pathology from 1999

Field of research
Background: With experience in clinical gynaecology, gynaecological oncology as well as pathology and basic science, research has been reflecting close collaboration between these fields. Clinical trials, patient material from routine gynaecologic pathology and clinical trials as well as in vitro cell models have been used. During the last years the research has been concentrating on preliminary stages on endometrial cancer (endometrial hyperplasias).
Translational research: Endometrial cancer is the fourth most common cancer in women in the western world developing through preliminary stages (endometrial hyperplasia). Endometrial hyperplasia is proceeding to cancer in 10-20 % of cases when left untreated. The morphometric method (D-score ) predicting risk of cancer development for each single patient divides cases into risk groups(1-3,6,7,13,18). The morphometric method, thus reflecting the phenotype of molecular changes, has been compared to several immunohistochemical and molecular derangements reflecting changes of the genotype (PTEN, MSH1, MSH2, MSH6, MSI, ploidy, flow cytometry)(8,9,11,12,14,15-17,19). Expression of apoptosis and proteins in the apoptotic cascade has been investigated after gestagen therapy in patient material. Cellular models imitating treatment regimens have been established . Effects of gestagen hormones on the expression of PRA, PRB, ER-alfa, ER- beta and AR have also been studied ( in press).
Clinical research: Gestagen hormones has a well known antiproliferative effect on endometrial mucosa and such treatment is used for conservative therapy of endometrial hyperplasia. No routines for such treatment have been established in Norway. A pilot study has been performed comparing the effect of high dose local application of levonorgestrel to per oral gestagen treatment in patients with endometrial hyperplasia (16,19).
Prospective randomized clinical study: Based on the results of the pilot study a multi- centre prospective randomized study on treatment of endometrial hyperplasia has been started comparing the effect of high dose local application of levonorgestrel to different per oral gestagen regimens. The results of this study will give new guide-lines to treatment of endometrial hyperplasia in Norway. This study gives an opportunity to combine clinical and biological approaches.

Publications
Publications last 5 years

Vereide AB, Kaino T, Sager G, Arnes M, Orbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
Gynecol Oncol. 2005 Nov 30; [Epub ahead of print]

Vereide AB, Kaino T, Sager G, Ørbo A. Bcl-2, BAX and apoptosis in endometrial hyperplasia after high dose gestagen therapy. A comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone Gynecol Oncol 2005; 97(3):15-25.

Baak JPA, Mutter GL, van Diest PJ, Uyterlinde A, Ørbo A et al. The molecular genetic-based EIN classification predicts better than the WHO 94 classification cancer progression risk of endometrial hyperplasia Cancer 2005;27 Apr.

Bertelsen EL, Endresen PC, Ørbo A , Sager G. Non-genomic cell growth inhibition by progesterone. Cell cycle retardation and induction of cell death. Anticancer Research 2004; 24(6):3749-3755.

Ørbo A, Kaino T, Arnes M, Kopp M, Eklo K. Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic marker for cancer development. A population based study from northern Norway with long term follow-up. Gynecol oncol 2004;1: 82-88

Ørbo A. Prognostic markers on survival of endometrial cancer patients in northern Norway. Invited Experts to Sociedad Iberoamericana Informacion Cientifica (SIIC) Tranlated to spanish: De sobrevida en pacientes con cancer de endometrio en el norte de noruega. Internet SIIC June 23th 2004.

Ørbo A, Arnesen T, Arnes M, Straume B. Resection margins in conization as prognostic marker for relapse in high-grade dysplasia of the uterine cervix in northern Norway: A retrospective long-term follow-up material. Gynecol.Oncol 2004; 93: 479-483

Vereide AB, Arnes M, Straume B, Maltau JM, Ørbo A Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia. A pilot study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone Gynecol Oncol 2003;92:526-533

Georg Sager, Anne Ørbo, Ragnhild Jæger and Catharina Engström: "Non-genomic effects of progestins - Inhibition of cell growth and increased intracellular levels of cyclic nucleotides" The Journal of Steroid Biochemistry and Molecular Biology 2003; 84 (1): 1-8.

A Ørbo, MN Nilsen, MS Arnes I Pettersen, K Larsen: “Expression of MLH1, MSH2, MSH6 and PTEN related to cancer development or coexistent cancer in 68 patients with endometrial hyperplasia and known follow-up” Int J Gynecol Pathol 2003;22:141-148.

M.Verelst, JMMaltau, A.Ørbo. Computerized morphometric study of paraurethral tissue in young versus elderly women. Neurourol Urodyn 2002; 21(6):529-33
11. A Ørbo, MN Nilsen, MS Arnes I Pettersen, K Larsen: “Expression of MLH1, MSH2, MSH6 and PTEN related to cancer development or coexistent cancer in 68 patients with endometrial hyperplasia and known follow-up” Int J Gynecol Pathol 2003;22:141-148.

A. Ørbo, M.Rydningen, B.Straume and S.Lysne: ”Significance of morphometric, DNA cytometric features and other prognostic markers on survival of endometrial cancer patients in Northern Norway” International Journal of Gynecological Cancer 12:49-56 2002

A.Ørbo, K..Eklo, M.Kopp and B.Straume: “A semiautomated test for microsattelite instability and its significance for prognosis of sporadic endometrial cancer in Northern Norway”. J. Gynecol Pathol 21, 27-33 (2002)

A.Ørbo, J.P.A. Baak: “The morphometric D-score is a more accurate predictor of endometrial hyperplasia to cancer than the WHO classification”. Surgical Pathology Update (Eds.: S.Hauptmann, M Dietel, M.Sobrinho-Simoes) pp. 512-515 (2001)

Jan P.A. Baak, Anne Orbo, Mark A. M. Broeckaert, Pau1 J. van Diest, et al.. ”Prospective nulticenter long-term evaluation of the computerized morphometric D-score to predict the outcome of endometrial hyperplasias.” Am J Surg Pathol, 25, 930-935 (2001)

Anne Ørbo and Åge Steffensen: "Endometrial cancer, vasculitis of the genital tract and occult temporal arteritis". Histopathology 38. p.178 (2001).

Anne Ørbo. "Successful cancer treatment - and so what?" (In Norwegian: "Vellykket kreftbehandling - men hva så?") Tidsskr Nor Lægeforen 120, 2740 (2000).

George L. Mutter and the Endometrial Collaborative Group (Jan P. A. Baak, Department of Pathology (DOP), Free University Hospital, Amsterdam, and Medical Center, Alkmaar, The Netherlands; Debra A. Bell, DOP, Massachusetts General Hospital, Boston, MA; Christine Bergeron, DOP, Laboratory CERBA, Cergy Pointoise, France; Christopher P. Crum, DOP, Brigham and Women's Hospital, Boston, MA; William C. Faquin, DOP, Massachusetts General Hospital, Boston, MA; Alex Ferenczy, DOP, McGill University, and The Sir Mortimer B.Davis Jewish General Hospital, Montreal, Quebec, Canada; Harold Fox, DOP, University of Manchester, Manchester, UK; Nancy B. Kiviat, DOP, University of Washington, Seattle, WA; Ming-Chieh Lin, DOP, Nat. Taiwan Univ. Hospital, Taiwan; George L. Mutter, DOP, Brigham and Women's Hospital, Boston, MA; Francisco F. Nogales, DOP, Universitad de Granada, Granada, Spain; Marisa R. Nucci, DOP, Brigham and Women's Hospital, Boston, MA; Anne Orbo, DOP, University Hospital of Tromso, Tromso, Norway; Andrew G. Ostor, DOP, Royal Women's Hospital, Melbourne, Australia; Ralph M. Richart, DOP and DOG, Columbia Presbyterian Medical Center, New York, NY; Mark H. Stoler, DOP, University of Virginia Health Sciences Center, Charlottesville, VA; Fattenah A. Tavassoli, DOP, Armed Forces Institute of Pathology, Washington, DC; William R. Welch, DOP, Brigham and Women's Hospital, Boston, MA; Michael Wells, DOP, University of Sheffield, Sheffield, UK.). "Endometrial Intraepithelial Neoplasia (EIN): Will it bring order into chaos?" Gynecol. Oncol. 76, 287-290 (2000).

Anne Ørbo, Jan PA Baak, Inger Kleivan, Sigrun Lysne , Per S. Prytz, Marc A.M. Broeckaert, André Slappendel and Hans J. Tichelaar: “Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long term retrospective study from northern Norway”. J. Clin. Pathology 53, 697-703 (2000).

Anne Ørbo, Jan P.A. Baak: ”Computerized morphometrical analysis in endometrial hyperplasia”. In Norwegian ”Databasert morfometrisk bildeanalyse ved endometriehyperplasi” Tidsskr Nor Lægeforen 120, 496-499 (2000).



Abstracts international congresses

A.Ørbo. Prognosticators of endometrial pre-cancers. Rikshospitalet København (oral presentasjon) 21.november 2003

A.Ørbo New prognosticators of cancer development in endometrial hyperplasia Abstract of the XXIVth International Congress of the International Academy of Pathology, Histopathology 2002 : 41( Supplement 1):8. Amsterdam Oct 5-10(Oral presentation Oct 8, 2002)

Endometrial hyperplasia, new diagnostics and new principles of treatment. Satellite
symposium to the Mirena – Helsinki Symposium 20 september, arranged by Schering Oral presentation, Helsinki, 19 sept, 2002)

A.Ørbo, JPA Baak. ”The morphometric D-score is a more accurate predictor of
progression of endometrisl hypeplasia to cancer than the WHO classification. 18th European Congress of Pathology” Berlin , Germany, Sept 8-13,2001 (Oral presentation Berlin Sept 13,2001)

A.Ørbo: ”Hormonal and premalignant changes of the endometrium”. Oral presentation. Invited lecture. Swedish society for pathologists. Linkøping Sweden May 3-5,2001

A.Ørbo, J.P.A.Baak, I.Kleivan, S.Lysne, Prytz PS, Broeckaert MAM, SlappendelA, Tischelaar HJ. Tomsø Norway and Alkmaar The Netherlands: ”Computerized morphometric measurements of endometrial hyperplasia with prognostic evaluation of risk of malignant development” XXXII Scandinavian Congress of obstetrics and gynecology Oslo 3-6 June . (Oral presentation Oslo 5.June 2000)



Abstracts national meetings

Vereide AB, Ørbo A. Årsmøte Nord-Norsk gynekologisk forening. Bodø 7-9 april,
2005. Levonovastudien.Oppdatering. 8april 2005

A.Ørbo AB Vereide. Endometriehyperplasi, kliniske , farmakologiske og molekyærbiologiske aspekter. Årsmøte Norsk gynekologisk forening Trondheim 9-11 september 2004.

A.Ørbo AB Vereide. Endometriehyperplasi, kliniske , farmakologiske og molekyærbiologiske aspekter. Årsmøte Norsk gynekologisk forening Trondheim 9-11 september 2004.

A.Ørbo. Endometriehyperplasi- nye muligheter for diagnostikk. Invitert foredrag Patologisk avdeling Ullevål universitetssykehus 22 april 2004

A.Ørbo Tildelingskriterier fra NFR til forskning . Seminar Nasjonalt senter for telemedisin 16 april 2004

A.Ørbo. Nasjonal studie for behandling av endometriehyperplasi. NGOF. Kirkenes 26 mars 2004

A.Ørbo. Diagnostikk av endometriehyperplasi. Fra klinikk til molekylærbiologi. Invitert fordrag (Norsk gynekologisk forening). Oslo 5 februar 2004

A.Ørbo AB Vereide Diagnostikk og behandling ved endometriehyperplasi. Molekylære mekanismer i endometriet. Symposium i gynekologi og obstetrikk ved Rikshospitalet i København. København 21. november 2003

A.Ørbo. Ny diagnostikk og behandling ved endometriehyperplasi. Invitert foredrag (Akerhus gynekologiske forening) Akershus ( Losby) 21.oktober 2003

A.Ørbo. Ny behandling ved endometriehyperplasi. Invitert foredrag (Hedmark og Oppland gynekologiske forening) Hamar 20. oktober 2003

A.Ørbo: Endometriehyperplasi – nye muligheter for behandling. Ullevål universitetssykehus Oslo Invitert fordrag Kvinnesenteret, Oslo 5 desember 2002

A.Ørbo: Levonova- ny behandling ved endometriehyperplasi. Invitert foredrag (Oslo gynekologiske forening) Oslo 5 desember 2002

AB Vereide , A.Ørbo,. Nye behandlingsprinsipper ved endometriehyperplasi. Nordnorsk gynekologisk forum, Lovun i Nordland, Foredrag 25-28 april, 2002

A.Ørbo. Endometriehyperplasi. Nye molekylærgenetiske prognostiske markører. Invitert foredrag (Oslo gynekologiske forening) Oslo 29 november 2001

A.Ørbo. Østrogen Kurs i farmakologi for bioingeniører. 9. november 2001

A.Ørbo. Hva skjer med pasienten etter vellykket kreftbehandling. Møte for Den nasjonale pasientforenigen for underlivskreft (DNK). Ritø 3. september 2001

A.Ørbo, AB Vereide. Nye behandlingsprinsipper ved endometriehyperplasi. Nordnorsk gynekologisk forum Hammerfest Foredrag 3.-5.mai 2001

A.Ørbo. Vellykket kreftbehandling – men hva så! Kreftforeningens omsorgssenter i Tromsø. Foredrag 19. april 2001.

35. A.Ørbo. Behandling med Levonova gestagenspiral ved endometriehyperplasi. Møte i Oslo Gynekologiske forening. (Foredrag 7 desember 2000)

A.Ørbo. Diagnostikk av endometriehyperplasi. Møte med gynekologer og patologer ved SiR. (Foredrag 7 november 2000)

A.Ørbo. Patologens rolle i diagnostikken av gynekologiske svulster. Samhandling om pasienter. Symposium Aasgaard sykehus. (Foredrag 5.september 2000)

A.Ørbo. Nyere metoder for diagnostikk av endometriehyperplasi. Oslo Gynekologisk Forening. Invitert av Schering Norge til avskjedsforelesning i auditoriet kvinneklinikken Gamle Rikshospitalets.(Foredrag 25 mai 2000).

A.Ørbo. Klinikerens rolle i patologidiagnostikk av gynekologiske preparater Videre-og etterutdanningskurs for gynekologer. (Foredrag 12 mai 2000).

A.Ørbo. Diagnostikk og behandling av endometriehyperplasi. Videre-og etterutdanningskurs for gynekologer. (Foredrag 12 mai 2000).

A.Ørbo. Nyere behandlingsmetoder ved endometriehyperplasi. Flerregionalt møte for gynekologer i Tromsø ( Foredrag 25 februar-2000).

A.Ørbo. Hvordan kan klinikerne bidra til bedret patologidiagnostikk. Nordnorsk Forum for Gynekologi og Obstetrikk. (Foredrag Stokmarknes 29 april 2000)

A.Ørbo. Nyere metoder for undersøkelse av endometriehyperplasi.Nordnorsk Forum for Gynekologi og Obstetrikk. (Foredrag Stokmarknes 28 april 2000)

G. Sager, E.Boadu, E.Sundkvist, R.Jaeger and A.Ørbo: Elevated egression of cGMP from transformed cells - Another form of acquired resistance? Farmakologisk selskaps vintermøte, Beito, 2000 (poster presentation).